Beremagene geperpavec-svdt
![Krystal Biotech, Priority Review Voucher, Vyjuvek, Beremagene geperpavec-svdt, Rare Pediatric Disease](https://pharmtales.com/wp-content/uploads/2023/08/Krystal-Biotech-Secures-100-Million-in-Sale-of-Priority-Review-Voucher.jpg)
Krystal Biotech Secures $100 Million in Sale of Priority Review Voucher
Anika Sharma
Krystal Biotech proudly announces the successful transaction of its Rare Pediatric Disease Priority Review Voucher (PRV), yielding an impressive $100 ...